SCHEMBL3635258

SCHEMBL3635258

CCOC(=O)c1onc2cc(Br)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TARBP2 Q15633 1/20 0.44
ELANE P08246 3/20 0.44
TBK1 Q9UHD2 1/20 0.43
LMNA P02545 2/20 0.43
TSHR P16473 1/20 0.43
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRB2 P47870 1/20 0.42
CACNA1F O60840 2/20 0.42
ABCB1 P08183 2/20 0.42
CACNA1D Q01668 2/20 0.42
CACNA1S Q13698 2/20 0.42
CACNA1C Q13936 2/20 0.42
ATM Q13315 2/20 0.42
MAPK1 P28482 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5985145 0.89 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2TARBP2ELANELMNA
SCHEMBL17437997 0.84 MAPT (0.48) ALDH1A1ELANETSHRMAPTHTT
SCHEMBL6819286 0.83 KDM4E (0.48) ALDH1A1SMN1; SMN2TARBP2ELANETSHR
SCHEMBL3639809 0.80 ESR1 (0.46) ALDH1A1SMN1; SMN2TARBP2TSHRMAPT
SCHEMBL6818394 0.80 KDM4E (0.51) ALDH1A1SMN1; SMN2ELANELMNATSHR
SCHEMBL17454396 0.79 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2TSHRMAPTHTT
SCHEMBL25170921 0.79 MAPT (0.39) ALDH1A1SMN1; SMN2LMNATSHRMAPT
SCHEMBL492231 0.78 TBK1 (0.48) ALDH1A1SMN1; SMN2TARBP2ELANETBK1
SCHEMBL17438051 0.77 PTPN1 (0.42) ALDH1A1SMN1; SMN2TSHRMAPK1MAPT
SCHEMBL25171020 0.77 KDM4E (0.49) ALDH1A1SMN1; SMN2TARBP2ELANEATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-01-02 US disclosed
EP-4436968-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2024-10-02 EP disclosed
CN-118201924-A Heterocyclic compounds and their use 万特斯治疗美国公司 2024-06-14 CN disclosed
WO-2023081441-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2023-05-11 WO disclosed
EP-2170072-A1 FARNESOID X RECEPTOR AGONISTS GlaxoSmithKline LLC (US) 2010-04-07 EP disclosed
WO-2008157270-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
EP-1940833-A1 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF Memory Pharmaceuticals Corporation (US) 2008-07-09 EP disclosed
WO-2007038367-A1 INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2007-04-05 WO disclosed
EP-1531812-A1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS SMITHKLINE BEECHAM CORPORATION (US) 2005-05-25 EP disclosed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO disclosed
WO-2004010995-A1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS SMITHKLINE BEECHAM CORPORATION (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CGAS, TDP1, CYP11B2 ALDH1A1 987/4885SMN1; SMN2 1142/4885TARBP2 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.